120 related articles for article (PubMed ID: 7045615)
1. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.
Costanzi JJ; Al-Sarraf M; Groppe C; Bottomley R; Fabian C; Neidhart J; Dixon D
Med Pediatr Oncol; 1982; 10(3):251-8. PubMed ID: 7045615
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Costanzi JJ; Fletcher WS; Balcerzak SP; Taylor S; Eyre HJ; O'Bryan RM; Al-Sarraf M; Frank J
Cancer; 1984 Feb; 53(4):833-6. PubMed ID: 6362830
[TBL] [Abstract][Full Text] [Related]
4. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
5. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Van Dyk JJ; Falkson G
Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
7. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
8. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
10. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Huncharek M; Caubet JF; McGarry R
Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
[TBL] [Abstract][Full Text] [Related]
11. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
Pullmann H; Muth M
Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
[No Abstract] [Full Text] [Related]
12. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Abdi EA; Hanson J; McPherson TA
Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
14. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Carbone PP; Costello W
Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
[TBL] [Abstract][Full Text] [Related]
15. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
Cascinelli N; Rümke P; MacKie R; Morabito A; Bufalino R
Cancer Immunol Immunother; 1989; 28(4):282-6. PubMed ID: 2702680
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Balch C; Troner M
Cancer; 1982 Apr; 49(7):1355-7. PubMed ID: 7037162
[TBL] [Abstract][Full Text] [Related]
17. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Chang CH; Horton J; Schoenfeld D; Salazer O; Perez-Tamayo R; Kramer S; Weinstein A; Nelson JS; Tsukada Y
Cancer; 1983 Sep; 52(6):997-1007. PubMed ID: 6349785
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
Rudolf Z; Plesnicar S
Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
[TBL] [Abstract][Full Text] [Related]
19. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
Green MD; MacKay IR; Buckley JC; Coates AS
Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma.
Verschraegen CF; Legha SS; Hersh EM; Plager C; Papadopoulos N; Burgess MA
Eur J Cancer; 1993; 29A(5):708-11. PubMed ID: 8471328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
